GlaxoSmithKline’s Lamictal Obtains MHLW Approval
This article was originally published in PharmAsia News
GlaxoSmithKline announced Oct. 16 it obtained a new drug approval for epilepsy drug Lamictal (lamotrigine)from Japan's Ministry of Health, Labor and Welfare. The drug is the first epilepsy drug in Japan that is indicated to treat patients from children to seniors and patients with intractable epilepsy. GSK plans to launch the drug in early December. (Click here for more - Japanese language
You may also be interested in...
UK start-up Iceni Diagnostics has secured funding to develop its test for the live, intact SARS-CoV-2 virus and the UK government is evaluating a lateral flow device based on the technology for testing saliva samples as part of efforts to step up rapid testing in the country. See what Iceni’s CEO Rob Field said about it here.
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.